Abstract：
Cholangiocarcinoma (CCA) is a deadly complication observed in the setting of primary sclerosing cholangitis (PSC). When symptoms develop and CCA is diagnosed, it is usually at an advanced stage. Median survival is less than 12 months. Early identification of CCA leads to improved outcomes. Although diagnostic tests have excellent specificity, they are plagued by low sensitivity. No surveillance strategies have been widely agreed upon, but most societies recommend measurement of serum carbohydrate antigen 19-9 and MRCP every 6 to 12 months in patients with PSC. Advances in understanding of the genetic factors that lead to CCA are awaited.
摘要：
胆管癌（CCA）是在原发性硬化性胆管炎（PSC）的背景下观察到的致命并发症。当症状发展并诊断出CCA时，它通常处于高级阶段。中位生存期少于12个月。早期识别CCA可改善结果。尽管诊断测试具有出色的特异性，他们受到低敏感度的困扰。没有广泛商定的监测策略，但大多数学会建议PSC患者每6~12个月检测血清糖类抗原19-9和MRCP.正在等待对导致CCA的遗传因素的理解的进展。
